These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 19134522

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tigecycline: a review of properties, applications, and analytical methods.
    da Silva LM, Nunes Salgado HR.
    Ther Drug Monit; 2010 Jun; 32(3):282-8. PubMed ID: 20431506
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ, Goff DA.
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [Abstract] [Full Text] [Related]

  • 6. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW, Neumiller JJ, Setter SM.
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
    Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections.
    Petersen PJ, Ruzin A, Tuckman M, Jones CH.
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):407-18. PubMed ID: 20226331
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
    Hawkey P, Finch R.
    Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.